Filing Details

Accession Number:
0001567619-18-005006
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-11-02 16:04:41
Reporting Period:
2018-10-31
Accepted Time:
2018-11-02 16:04:41
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1603756 Axonics Modulation Technologies Inc. AXNX () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1583977 Cormorant Asset Management, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
1599214 Bihua Chen C/O Cormorant Asset Management, Lp
200 Clarendon Street, 52Nd Floor
Boston MA 02116
Yes No Yes No
1618442 Cormorant Global Healthcare Master Fund, Lp 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
1618451 Cormorant Global Healthcare Gp, Llc 200 Clarendon Street, 52Nd Floor
Boston MA 02116
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-10-31 599,999 $0.00 599,999 No 4 C Indirect See Footnote
Common Stock Acquisiton 2018-10-31 552,495 $0.00 1,152,494 No 4 C Indirect See Footnotes
Common Stock Acquisiton 2018-10-31 133,333 $15.00 1,285,827 No 4 P Indirect See Footnotes
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See Footnote
No 4 C Indirect See Footnotes
No 4 P Indirect See Footnotes
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B-2 Convertible Preferred Stock Disposition 2018-10-31 599,999 $0.00 599,999 $0.00
Common Stock Series C Convertible Preferred Stock Disposition 2018-10-31 552,495 $0.00 552,495 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Direct
Footnotes
  1. Shares of Series B-2 Convertible Preferred Stock ("Series B-2 Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.
  2. Shares of Series C Convertible Preferred Stock ("Series C Preferred Stock") were convertible at any time at the holder's election, without payment of additional consideration, and had no expiration date but converted automatically upon the closing of the Issuer's initial public offering.
  3. Shares reported herein are held by Cormorant Global Healthcare Master Fund, LP (the "Master Fund"), Cormorant Private Healthcare Fund I, LP (the "Fund I"), and a managed account (the "Account"). Cormorant Asset Management, LP ("Cormorant") serves as the investment manager of the Master Fund, Fund I, and the Account. Bihua Chen serves as manager of the general partner of Cormorant. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934 or for any other purpose.
  4. The Series B-2 Preferred Stock represented, on an as-converted basis (i) 126,375 shares of Common Stock held by the Master Fund, (ii) 450,000 shares of Common Stock held by Fund I, and (iii) 23,624 shares of Common Stock held by the Account.
  5. The Series C Preferred Stock represented, on an as-converted basis (i) 96,985 shares of Common Stock held by the Master Fund, (ii) 435,788 shares of Common Stock held by Fund I, and (iii) 19,722 shares of Common Stock held by the Account.
  6. Shares reported herein as purchased on October 31, 2018 represent (i) 122,853 shares purchased by the Master Fund, and (ii) 10,480 shares purchased by the Account.